Sales in the PPI market are↑ 60% over the past 3 years

Immediately after Ranitidine outbreak, the prescription expanded ↑24%

The PPI anti- ulcer drug market has changed rapidly since the Ranitidine crisis.

 

The market expanded sharply shortly after Ranitidine crisis, but growth has slowed down in the past year.

 

Esomeprazole, Rabeprazole, and Ilaprazole enjoyed the reflective effect of Ranitidine crisis.

 

On the other hand, in the case of Lansoprazole and Pantoprazole, it was difficult to expand their influence on the Ranitidine situation.

 

◆PPI market grows 61% compared to just before Ranitidine crisis According to UBIST, a pharmaceutical market research firm on the 4th, the amount of outpatient prescriptions for PPI-based anti- ulcer drugs last year was 732.5 billion won.

 

Compared to 454.9 billion won in 2018, it increased by 61% in three years.

 

PPI-based anti- ulcer drugs are the treatments that treat peptic ulcers and gastroesophageal reflux diseases by blocking proton pumps, the final stage of gastric acid secretion, and maintaining a high hydrogen ion index (pH) in the stomach.

 

The reason for the rapid expansion of the market is the Ranitidine incident that occurred in 2019.

 

In June 2019, impurities were detected in Ranitidine, an H2 receptor antagonist-based anti- ulcer drug.

 

Eventually, the sale of this drug was stopped.

 

When Ranitidine, the most commonly used in the market, was removed from the market, and PPI-based drugs enjoyed reflective effects.

 

The annual prescription performance of PPI drugs by year increased to around 10% every year until 2018.

 

In 2019, when the Ranitidine crisis occurred, the increase increased by 18% year-on-year.

 

Then, in 2020, when Ranitidine was completely removed from the market, it increased 24% year-on-year.

 

However, the growth trend that has continued since Ranitidine crisis last year seems to have slowed somewhat.

 

The prescription amount of PPI-based drugs increased by 10% to 732.5 billion won last year.

 

Some analysts say that the rapid growth of K-cab, a new P-CAB anti- ulcer drug, and the prolonged COVID-19 crisis have played a combined role.

 

HK inno.N's K-Cab has posted 30.9 billion won in prescription performance that year since its release in March 2019.

 

In 2020, it more than doubled to 76.1 billion won.

 

Last year, it recorded 109.6 billion won, exceeding 100 billion won in prescriptions in the third year of its launch.

 

◆Esomeprazole·Ilaprazole vs Lansoprazole·Pantoprazole Esomeprazole, Ilaprazole, and Rabeprazole greatly expanded their influence after Ranitidine crisis.

 

The drug that enjoyed the greatest reflective effect is Esomeprazole.

 

Esomeprazole posted 319.4 billion won in prescription last year.

 

Compared to 19.8 billion won in 2018, before Ranitidine crisis, it increased 63%.

 

In the case of Rabeprazole, it increased 34% from 125.9 billion won to 169.1 billion won during the same period.

 

Ilaprazole increased 33% from 28.3 billion won to 37.6 billion won.

 

In the case of Lansoprazole and Pantoprazole, it is analyzed that they did not enjoy the reflective effect properly despite the gap of Ranitidine.

 

Lansoprazole's prescription amount increased only 4% from 49.1 billion won in 2018 to 51 billion won last year.

 

Pantoprazole increased 4% from 34.7 billion won to 36.3 billion won during the same period.

 

Last year, both ingredients showed a decrease in prescription performance compared to the previous year.